Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration.

Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y.

Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.

PMID:
23318685
[PubMed - indexed for MEDLINE]
Free Article
2.

Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Green JM, Leu K, Worth A, Mortensen RB, Martinez DK, Schatz PJ, Wojchowski DM, Young PR.

Exp Hematol. 2012 Jul;40(7):575-87. doi: 10.1016/j.exphem.2012.02.007. Epub 2012 Mar 6.

PMID:
22406924
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Silica as a matrix for encapsulating proteins: surface effects on protein structure assessed by circular dichroism spectroscopy.

Calabretta PJ, Chancellor MC, Torres C, Abel GR, Niehaus C, Birtwhistle NJ, Khouderchah NM, Zemede GH, Eggers DK.

J Funct Biomater. 2012 Aug 2;3(3):514-27. doi: 10.3390/jfb3030514.

PMID:
24955630
[PubMed]
Free PMC Article
4.

Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats.

Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y.

Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310. Epub 2011 Dec 22.

PMID:
22188389
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain.

Tong SE, Daniels SE, Black P, Chang S, Protter A, Desjardins PJ.

J Clin Pharmacol. 2012 May;52(5):717-28. doi: 10.1177/0091270011405496. Epub 2011 Jun 9.

PMID:
21659629
[PubMed - indexed for MEDLINE]
6.

Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.

Woodburn KW, Schatz PJ, Wilson S, Fong KL, Wagner VO, Gudi R, Krsmanovic L, Paranjpe M, Shah SA.

Drug Chem Toxicol. 2011 Jul;34(3):240-9. doi: 10.3109/01480545.2010.510140.

PMID:
21649477
[PubMed - indexed for MEDLINE]
7.

Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.

Woodburn KW, Schatz PJ, Fong KL, Beaumier P.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):121-9.

PMID:
20378000
[PubMed - indexed for MEDLINE]
8.

A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.

Woodburn KW, Fan Q, Schatz PJ, Wilson SD, Fong KL, Norton D.

Drug Chem Toxicol. 2010 Jan;33(1):28-37. doi: 10.3109/01480540903176610.

PMID:
19995307
[PubMed - indexed for MEDLINE]
9.

High-affinity FGFR2 binding peptides derived from the native epitope of the KGF ligand.

Pan Y, Angell YM, Green JM, Wright KL, Miguel J, Schatz PJ, Holmes CP.

Adv Exp Med Biol. 2009;611:511-2. No abstract available.

PMID:
19400289
[PubMed - indexed for MEDLINE]
10.

Discovery and optimization of a TRAIL R2 agonist for cancer therapy.

Angell YM, Bhandari A, De Francisco MN, Frederick BT, Green JM, Leu K, Leuther K, Sana R, Schatz PJ, Whitehorn EA, Wright K, Holmes CP.

Adv Exp Med Biol. 2009;611:101-3. No abstract available.

PMID:
19400112
[PubMed - indexed for MEDLINE]
11.

Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Spainhour CB, Norton D.

Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):155-63. doi: 10.1111/j.1742-7843.2008.00347.x. Epub 2008 Dec 16.

PMID:
19143750
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys.

Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Ferrell T, Spainhour CB, Norton D.

Haematologica. 2008 Sep;93(9):1376-9. doi: 10.3324/haematol.12896. Epub 2008 Jun 2.

PMID:
18519511
[PubMed - indexed for MEDLINE]
Free Article
13.

Designing better coumarin-based fluorogenic substrates for PTP1B.

Holmes CP, Macher N, Grove JR, Jang L, Irvine JD.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3382-5. doi: 10.1016/j.bmcl.2008.04.021. Epub 2008 Apr 13.

PMID:
18442911
[PubMed - indexed for MEDLINE]
14.

PTP1B inhibitors: synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffold.

Holmes CP, Li X, Pan Y, Xu C, Bhandari A, Moody CM, Miguel JA, Ferla SW, De Francisco MN, Frederick BT, Zhou S, Macher N, Jang L, Irvine JD, Grove JR.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2719-24. doi: 10.1016/j.bmcl.2008.03.007. Epub 2008 Mar 6.

PMID:
18372175
[PubMed - indexed for MEDLINE]
15.

Preclinical safety and pharmacology of Hematide, a peptidic erythropoiesis stimulating agent (ESA), in rats and monkeys.

Woodburn KW, Schatz PJ, Fong KL, Wilson SD, Ferrell T, Spainhour CB, Norton D.

Drug Chem Toxicol. 2008;31(2):229-44. doi: 10.1080/01480540701873186 .

PMID:
18330784
[PubMed - indexed for MEDLINE]
16.

Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.

Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ.

Exp Hematol. 2007 Aug;35(8):1201-8.

PMID:
17662888
[PubMed - indexed for MEDLINE]
17.

Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia.

Shamloo M, Soriano L, von Schack D, Rickhag M, Chin DJ, Gonzalez-Zulueta M, Gido G, Urfer R, Wieloch T, Nikolich K.

Eur J Neurosci. 2006 Nov;24(10):2705-20.

PMID:
17156197
[PubMed - indexed for MEDLINE]
18.

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW.

Exp Hematol. 2006 Oct;34(10):1303-11.

PMID:
16982323
[PubMed - indexed for MEDLINE]
19.

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM.

Blood. 2006 Sep 15;108(6):1830-4. Epub 2006 May 23.

PMID:
16720830
[PubMed - indexed for MEDLINE]
Free Article
20.

Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists.

Yanofsky SD, Shen ES, Holden F, Whitehorn E, Aguilar B, Tate E, Holmes CP, Scheuerman R, MacLean D, Wu MM, Frail DE, López FJ, Winneker R, Arey BJ, Barrett RW.

J Biol Chem. 2006 May 12;281(19):13226-33. Epub 2006 Mar 15.

PMID:
16540466
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk